12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data.

ABSTRACT:

Background

Real-world data on liraglutide for pediatric obesity is limited, especially in public healthcare systems of low- and middle-income countries.

Objective

To evaluate the real-world effectiveness and safety of liraglutide in managing severe obesity among children and adolescents with severe obesity treated at a public quaternary hospital in Brazil.

Methods

This cohort study included patients aged 6-17.9 years with BMI Z-score (Z-BMI) ≥+3, treated with liraglutide (up to 3.0 mg/day) and lifestyle intervention. Outcomes included changes in BMI, Z-BMI, weight, WHtR, metabolic markers, and adverse events over 3 months, 6 months and 12 months.

Results

Of 74 patients, 55 completed 6 months and 22 completed 12 months. In patients aged 6-12 years (n=23), median

SUBMITTER: Cominato L 

PROVIDER: S-EPMC12491053 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature